In this study, we will provide evidence of the feasibility of protein-based PLC-γ1 inhibitors as potent antitumour agents due to their ability to block PLC-γ1 activity efficiently, thereby inhibiting the proliferation as well as the EGF-induced migration of EGFR/c-erbB-2-positive breast cancer cells. This evidence concerns the gene EGF and breast carcinoma.